Johanna C. Bendell | Hematology Oncology | Nashville, TN

Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors

Enrollment Status: Recruiting

Publish Date: January 29, 2025

Intervention Type: Combination product, Drug

Study Drug: MCLA-158

Study Phase: Phase 1/Phase 2

An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies

Enrollment Status: Active_not_recruiting

Publish Date: December 04, 2025

Intervention Type: Drug

Study Drug: Avelumab

Study Phase: Phase 3

A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants With Gastrointestinal Malignancies

Enrollment Status: Active_not_recruiting

Publish Date: December 01, 2025

Intervention Type: Drug

Study Drugs: Zimberelimab, Nab-Paclitaxel, Gemcitabine, AB680 CD73 Inhibitor

Study Phase: Phase 1

A Phase 1 Study of LY3127804 as Monotherapy and in Combination With Ramucirumab in Patients With Advanced Solid Tumors

Enrollment Status: Terminated

Publish Date: October 23, 2025

Intervention Type: Drug

Study Phase: Phase 1

A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer (ECHO-206)

Enrollment Status: Terminated

Publish Date: October 21, 2025

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer

Enrollment Status: Completed

Publish Date: October 20, 2025

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Drug Combinations in Adult Patients With Advanced or Metastatic BRAF V600 Colorectal Cancer

Enrollment Status: Terminated

Publish Date: September 22, 2025

Intervention Type: Biological, Drug

Study Drugs: Dabrafenib, Trametinib, Spartalizumab, LTT-462, LXH-254, TNO-155

Study Phase: Phase 1

Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma

Enrollment Status: Completed

Publish Date: September 17, 2025

Intervention Type: Drug

Study Drugs: Gevokizumab, Bevacizumab, Modified FOLFOX6, FOLFIRI, Ramucirumab, Paclitaxel, Cabozantinib

Study Phase: Phase 1

Phase 2 Study of ZW25 Plus First-line Combination Chemotherapy in HER2-Expressing Gastrointestinal (GI) Cancers, Including Gastroesophageal Adenocarcinoma (GEA), Biliary Tract Cancer (BTC), and Colorectal Cancer (CRC)

Enrollment Status: Completed

Publish Date: September 12, 2025

Intervention Type: Drug

Study Drugs: ZW25 (Zanidatamab), Capecitabine, Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab, Gemcitabine

Study Phase: Phase 2

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Enrollment Status: Completed

Publish Date: August 14, 2025

Intervention Type: Drug

Study Drugs: INCAGN01876, Nivolumab, Ipilimumab

Study Phase: Phase 1/Phase 2

Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer

Enrollment Status: Active_not_recruiting

Publish Date: August 03, 2025

Intervention Type: Drug

Study Phase: Phase 2

A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies

Enrollment Status: Completed

Publish Date: August 03, 2025

Intervention Type: Drug

Study Phase: Phase 1

A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer

Enrollment Status: Completed

Publish Date: July 22, 2025

Intervention Type: Drug

Study Drugs: Etrumadenant, Zimberelimab, AB680, Enzalutamide, Docetaxel

Study Phase: Phase 1/Phase 2

A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of SRK-181 Alone and in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)

Enrollment Status: Completed

Publish Date: April 29, 2025

Intervention Type: Biological

Study Drugs: SRK-181, Anti-PD-(L)1 Antibody Therapy

Study Phase: Phase 1

A Phase 1/1b, Open-Label, Multicenter, Dose-Escalation Study of RMC 5552 Monotherapy in Adult Subjects With Relapsed/Refractory Solid Tumors

Enrollment Status: Completed

Publish Date: April 15, 2025

Intervention Type: Drug

Study Drug: RMC-5552

Study Phase: Phase 1

A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer

Enrollment Status: Completed

Publish Date: April 04, 2025

Intervention Type: Drug

Study Drug: Fruquintinib

Study Phase: Phase 3

A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer

Enrollment Status: Completed

Publish Date: March 17, 2025

Intervention Type: Biological

Study Drug: Margetuximab+Pembrolizumab

Study Phase: Phase 1/Phase 2

A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients With Unresectable or Metastatic Neoplasms

Enrollment Status: Completed

Publish Date: March 06, 2025

Intervention Type: Biological

Study Drug: MGD019 Bispecific DART Protein Binding PD-1 and CTLA-4

Study Phase: Phase 1

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Enrollment Status: Completed

Publish Date: February 14, 2025

Intervention Type: Drug

Study Phase: Phase 3

A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors

Enrollment Status: Completed

Publish Date: December 24, 2024

Intervention Type: Drug

Study Drug: CYT-0851

Study Phase: Phase 1/Phase 2

PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer

Enrollment Status: Terminated

Publish Date: November 26, 2024

Intervention Type: Drug

Study Drug: Trilaciclib

Study Phase: Phase 3

MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer

Enrollment Status: Completed

Publish Date: November 26, 2024

Intervention Type: Drug

Study Phase: Phase 2

Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma

Enrollment Status: Completed

Publish Date: October 31, 2024

Intervention Type: Drug, Device

Study Drugs: Gemcitabine, Nab-paclitaxel

Study Phase: Phase 3

A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)

Enrollment Status: Completed

Publish Date: September 27, 2024

Intervention Type: Drug

Study Phase: Phase 1

An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus Pembrolizumab in Patients With Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Enrollment Status: Completed

Publish Date: July 31, 2024

Intervention Type: Drug

Study Drugs: Ramucirumab, Pembrolizumab

Study Phase: Phase 1

A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors

Enrollment Status: Completed

Publish Date: June 04, 2024

Intervention Type: Drug

Study Phase: Phase 1

A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid Tumors

Enrollment Status: Completed

Publish Date: April 22, 2024

Intervention Type: Drug

Study Drug: HER2/41BB Bispecific

Study Phase: Phase 1

A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

Enrollment Status: Active_not_recruiting

Publish Date: April 05, 2024

Intervention Type: Drug

Study Drug: PT-112

Study Phase: Phase 2

A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of MORAb-066, a Humanized Monoclonal Antibody to Human Tissue Factor, in Patients With Advanced or Metastatic Breast, Pancreatic, Colorectal, or Non-Small Cell Lung Cancer (Adenocarcinoma) Malignancies

Enrollment Status: Completed

Publish Date: March 29, 2024

Intervention Type: Drug

Study Phase: Phase 1

A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1592 In Patients With Solid Tumors Likely to Express NaPi2b

Enrollment Status: Terminated

Publish Date: March 15, 2024

Intervention Type: Biological

Study Drug: XMT-1592

Study Phase: Phase 1

Phase I, First-in-Human, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of M6223, an Inhibitor of TIGIT, as Single Agent and in Combination With Bintrafusp Alfa (Anti-PDL1/ TGFß Trap) in Participants With Metastatic or Locally Advanced Solid Unresectable Tumors

Enrollment Status: Completed

Publish Date: December 08, 2023

Intervention Type: Drug

Study Phase: Phase 1

A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination With Systemic Anti-Cancer Therapies in Subjects With Advanced Solid Tumors

Enrollment Status: Completed

Publish Date: July 03, 2023

Intervention Type: Drug

Study Drugs: TPST-1120, Nivolumab

Study Phase: Phase 1

Ph1b/2 Open-Label,Multicenter Dose-Esc & Dose-Exp Study of Combo RMC4630 & Cobimetinib in Participants w/Relapsed/Refractory Solid Tumors & Ph1b Study of RMC4630 w/Osimertinib in Participants w/EGFR Mutation+,Locally Adv or Meta NSCLC

Enrollment Status: Completed

Publish Date: June 26, 2023

Intervention Type: Drug

Study Drugs: RMC-4630, Cobimetinib, Osimertinib

Study Phase: Phase 1/Phase 2

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)

Enrollment Status: Completed

Publish Date: March 20, 2023

Intervention Type: Drug

Study Drugs: CB-839, Cabozantinib

Study Phase: Phase 2

A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer

Enrollment Status: Completed

Publish Date: November 22, 2022

Intervention Type: Drug

Study Phase: Phase 1

An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Enrollment Status: Completed

Publish Date: October 06, 2022

Intervention Type: Drug

Study Drugs: Avapritinib, Regorafenib

Study Phase: Phase 3

A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

Enrollment Status: Completed

Publish Date: September 23, 2022

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors

Enrollment Status: Terminated

Publish Date: July 15, 2022

Intervention Type: Drug, Biological

Study Drugs: IL-2, Fludarabine, Cyclophosphamide

Study Phase: Phase 1

A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer

Enrollment Status: Completed

Publish Date: June 28, 2022

Intervention Type: Drug

Study Drugs: Olaratumab, Nab-paclitaxel, Gemcitabine

Study Phase: Phase 1/Phase 2

A Phase 1, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 DART® Protein, in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory B7-H3-Expressing Tumors

Enrollment Status: Completed

Publish Date: May 19, 2022

Intervention Type: Biological

Study Phase: Phase 1

Phase 1 Trial of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta (VSV-IFNβ-NIS) Monotherapy and in Combination With Avelumab, in Patients With Refractory Solid Tumors

Enrollment Status: Completed

Publish Date: April 27, 2022

Intervention Type: Biological

Study Phase: Phase 1

A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors

Enrollment Status: Completed

Publish Date: April 19, 2022

Intervention Type: Drug, Biological

Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab

Study Phase: Phase 1/Phase 2

A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer

Enrollment Status: Completed

Publish Date: April 08, 2022

Intervention Type: Drug

Study Drugs: LY3023414, Midazolam, Fulvestrant, Pemetrexed, Cisplatin, Abemaciclib, Letrozole

Study Phase: Phase 1

A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 as Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia Patients Not Eligible for Intensive Induction Therapy.

Enrollment Status: Terminated

Publish Date: April 05, 2022

Intervention Type: Drug

Study Drugs: AZD2811, Azacitidine, Venetoclax

Study Phase: Phase 1

A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer

Enrollment Status: Completed

Publish Date: May 11, 2021

Intervention Type: Drug

Study Phase: Phase 2

A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer

Enrollment Status: Completed

Publish Date: March 01, 2021

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase 1b/2 Study of Ramucirumab in Combination With LY2875358 in Patients With Advanced Cancer

Enrollment Status: Completed

Publish Date: December 19, 2020

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Enrollment Status: Completed

Publish Date: November 24, 2020

Intervention Type: Drug, Other

Study Phase: Phase 3

Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen

Enrollment Status: Completed

Publish Date: October 19, 2020

Intervention Type: Biological, Drug

Study Phase: Phase 3

A Phase 1 Study of SGN-CD47M in Patients With Advanced Solid Tumors

Enrollment Status: Terminated

Publish Date: September 17, 2020

Intervention Type: Drug

Study Phase: Phase 1

Dr. Johanna C. Bendell

Overview

Insurance

Locations

Clinical Research

60 Clinical Trials

188 Total Publications

Select Physical Therapy Holdings Inc

Jennie Stuart Medical Center Inc

Vanderbilt Health Clinicians, LLC

Areas of Expertise